{
  "metadata": {
    "case_id": 51,
    "model": "Claude-4.5-Sonnet",
    "timestamp": "2025-11-29T16:41:39.032080",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/51_NCT00977431.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Claude-4.5-Sonnet/51_Claude-4.5-Sonnet.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 5,
      "similarity_matrix": [
        [
          0.78,
          0.72,
          0.78,
          0.9,
          0.96
        ],
        [
          0.93,
          0.96,
          0.92,
          0.6,
          0.6
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 4,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "label": "Regimen U",
            "type": "EXPERIMENTAL",
            "description": "BIBW2992 + Radiotherapy",
            "interventionNames": [
              "Procedure: Radiotherapy",
              "Drug: BIBW2992"
            ]
          },
          "pred_item": {
            "label": "Regimen U: Afatinib + RT (Dose Escalation 40 mg)",
            "type": "EXPERIMENTAL",
            "description": "Patients with unmethylated MGMT promoter received afatinib 40 mg/day during both the RT phase (6 weeks, 60 Gy total dose) and maintenance, without concomitant TMZ.",
            "interventionNames": [
              "DRUG: Afatinib 40 mg/day (RT phase and maintenance)",
              "RADIATION: Radiotherapy (RT)"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "label": "Regimen M",
            "type": "EXPERIMENTAL",
            "description": "BIBW2992 + Temozolomide + Radiotherapy",
            "interventionNames": [
              "Drug: Temozolomide",
              "Drug: BIBW2992",
              "Procedure: Radiotherapy"
            ]
          },
          "pred_item": {
            "label": "Regimen M: Afatinib + TMZ + RT (Dose Escalation 30 mg)",
            "type": "EXPERIMENTAL",
            "description": "Patients with methylated MGMT promoter received afatinib 30 mg/day during the RT phase (6 weeks, 60 Gy total dose) and 40 mg/day during maintenance, plus TMZ 75 mg/m² daily during RT, followed by TMZ maintenance cycles (150 mg/m² in cycle 1, 200 mg/m² in cycles 2–6, days 1–5 of each 28-day cycle for up to 6 cycles).",
            "interventionNames": [
              "DRUG: Afatinib 30 mg/day (RT phase)",
              "DRUG: Afatinib 40 mg/day (maintenance)",
              "DRUG: Temozolomide (TMZ)",
              "RADIATION: Radiotherapy (RT)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 5,
      "pred_count": 6,
      "similarity_matrix": [
        [
          0.2,
          0.2,
          0.18,
          0.18,
          0.96,
          0.25
        ],
        [
          0.3,
          0.2,
          0.3,
          0.3,
          0.3,
          0.88
        ],
        [
          0.82,
          0.78,
          0.9,
          0.82,
          0.2,
          0.4
        ],
        [
          0.35,
          0.2,
          0.4,
          0.2,
          0.3,
          0.93
        ],
        [
          0.82,
          0.78,
          0.9,
          0.82,
          0.35,
          0.35
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 4,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Temozolomide",
            "description": "During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)",
            "armGroupLabels": [
              "Regimen M"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Temozolomide (TMZ)",
            "description": "Temozolomide administered orally at 75 mg/m² once daily during the 6-week radiotherapy phase (days 1–42), followed by a 4-week TMZ-free phase, then TMZ maintenance for up to 6 cycles (28-day cycles, days 1–5: 150 mg/m² in cycle 1, 200 mg/m² in cycles 2–6).",
            "armGroupLabels": [
              "Regimen M: Afatinib + TMZ + RT (Dose Escalation 20 mg)",
              "Regimen M: Afatinib + TMZ + RT (Dose Escalation 30 mg)",
              "Regimen M: Afatinib + TMZ + RT (Dose Escalation 40 mg)"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 3,
          "score": 0.3,
          "status": "matched",
          "ref_item": {
            "type": "PROCEDURE",
            "name": "Radiotherapy",
            "description": "Day 1 to day 42",
            "armGroupLabels": [
              "Regimen U"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Afatinib 40 mg/day (maintenance)",
            "description": "Afatinib administered orally at 40 mg once daily during the maintenance phase (after completion of radiotherapy) until disease progression or undue adverse reaction.",
            "armGroupLabels": [
              "Regimen M: Afatinib + TMZ + RT (Dose Escalation 20 mg)",
              "Regimen M: Afatinib + TMZ + RT (Dose Escalation 30 mg)",
              "Regimen U: Afatinib + RT (Dose Escalation 20 mg)"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 2,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "BIBW2992",
            "description": "Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT",
            "armGroupLabels": [
              "Regimen M"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Afatinib 40 mg/day (RT phase and maintenance)",
            "description": "Afatinib administered orally at 40 mg once daily during both the 6-week radiotherapy phase (days 1–42) and the maintenance phase until disease progression or undue adverse reaction.",
            "armGroupLabels": [
              "Regimen M: Afatinib + TMZ + RT (Dose Escalation 40 mg)",
              "Regimen U: Afatinib + RT (Dose Escalation 40 mg)"
            ]
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 5,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "type": "PROCEDURE",
            "name": "Radiotherapy",
            "description": "Day 1 to day 42",
            "armGroupLabels": [
              "Regimen M"
            ]
          },
          "pred_item": {
            "type": "RADIATION",
            "name": "Radiotherapy (RT)",
            "description": "Radiotherapy administered at 2 Gy per fraction on 5 days per week for 6 weeks (total dose of 60 Gy) during the initial RT phase.",
            "armGroupLabels": [
              "Regimen M: Afatinib + TMZ + RT (Dose Escalation 20 mg)",
              "Regimen M: Afatinib + TMZ + RT (Dose Escalation 30 mg)",
              "Regimen M: Afatinib + TMZ + RT (Dose Escalation 40 mg)",
              "Regimen U: Afatinib + RT (Dose Escalation 20 mg)",
              "Regimen U: Afatinib + RT (Dose Escalation 40 mg)"
            ]
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": 0,
          "score": 0.82,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "BIBW2992",
            "description": "Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT",
            "armGroupLabels": [
              "Regimen U"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Afatinib 20 mg/day (RT phase)",
            "description": "Afatinib administered orally at 20 mg once daily during the 6-week radiotherapy phase (days 1–42).",
            "armGroupLabels": [
              "Regimen M: Afatinib + TMZ + RT (Dose Escalation 20 mg)",
              "Regimen U: Afatinib + RT (Dose Escalation 20 mg)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.9
        ],
        [
          0.93
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Patients With Investigator Defined Dose Limiting Toxicities (DLT) During the RT Phase",
            "description": "Adverse event (AE) related to afatinib with any one criteria; Hematological: Common terminology criteria for adverse events (CTCAE) Grade 4 neutropenia (Absolute neutrophil count, including bands \\<500/cubic millimeter (mm³)) for \\>7 days, CTCAE Grade 3 or 4 neutropenia of any duration associated with fever \\>38.3 Celsius, CTCAE Grade 3 thrombocytopenia (platelet count \\<50000 - 25000/mm³), All other toxicities of CTCAE Grade ≥3 leading interruption of treatment \\> 14 days.\n\nNon-hematological: CTCAE Grade ≥3 nausea or vomiting despite appropriate use of standard anti-emetics for ≥3 days, CTCAE Grade ≥3 diarrhea despite appropriate use of standard anti-diarrheal therapy for ≥3 days, CTCAE Grade ≥3 rash despite standard medical management and lasting \\>7 days, CTCAE Grade ≥2 cardiac left ventricular function, CTCAE Grade ≥2 worsening of renal function as measured by serum creatinine, newly developed proteinuria or decrease in glomerular filtration rate, All other toxicities of CTCAE Grade ≥3.",
            "timeFrame": "6 weeks"
          },
          "pred_item": null
        },
        {
          "ref_idx": 1,
          "pred_idx": 0,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "measure": "Maximum Tolerated Dose (MTD) of Afatinib",
            "description": "The MTD was defined as the highest afatinib dose level, at which no more than 1 out of 6 patients experienced drug-related DLT, i.e. the highest afatinib dose with a DLT incidence ≤17%. A separate MTD was determined for afatinib and RT (Regimen U), and for afatinib, TMZ, and RT (Regimen M).",
            "timeFrame": "6 weeks"
          },
          "pred_item": {
            "measure": "Maximum Tolerated Dose (MTD) of Afatinib in Combination with RT",
            "description": "The highest afatinib dose level at which no more than one of six patients experienced dose-limiting toxicity (DLT), i.e., the highest afatinib dose with a DLT incidence ≤17%, during the 6-week radiotherapy (RT) phase.",
            "timeFrame": "During the 6-week RT phase (approximately 42 days)"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 3,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.93,
          0.08,
          0.05
        ],
        [
          0.05,
          0.94,
          0.07
        ],
        [
          0.1,
          0.05,
          0.94
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "measure": "Incidence and Intensity of Adverse Events (AE) According to Common Terminology Criteria of Adverse Events (CTCAE v.3.0)",
            "description": "Incidence and intensity of adverse events (AE) according to Common Terminology Criteria of Adverse Events (CTCAE v.3.0). The CTCAE grades are: 1 (mild AE), 2 (moderate AE), 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related to AE).",
            "timeFrame": "From the first administration of trial medication until 4 weeks after the last administration of trial medication, up to approximately 338 weeks"
          },
          "pred_item": {
            "measure": "Incidence and Intensity of Adverse Events (AEs)",
            "description": "Assessed by physical examination, hematologic and chemistry laboratory values, vital signs, and electrocardiography scans. AEs were graded by CTCAE version 3.0. Serious AEs (SAEs) were also evaluated.",
            "timeFrame": "Throughout the treatment period and follow-up"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "measure": "The Objective Tumour Response According to the Macdonald Criteria",
            "description": "Objective response was defined as a best overall response of complete response (CR) or partial response (PR). The best overall response was the best overall response to trial medication according to the Macdonald criteria recorded since the first administration of trial medication and until the earliest of disease progression, death, or start of further anti-cancer treatment. Tumour response was assessed based on local radiological image evaluation by the investigators according to the Macdonald criteria: Complete Response (CR): Disappearance of all enhancing tumour on consecutive Magnetic resonance imaging (MRI) scans at least 28 days apart, off steroids, and neurologically stable or improved. Partial Response (PR): At least 50% reduction in size of enhancing tumour on consecutive MRI scans at least 28 days apart, steroids stable or reduced, and neurologically stable or improved.",
            "timeFrame": "From the first administration of trial medication until 4 weeks after the last administration of trial medication, up to approximately 338 weeks"
          },
          "pred_item": {
            "measure": "Objective Tumor Response Rate",
            "description": "Assessed by the investigator according to the Macdonald criteria, as measured by cerebral gadolinium-enhanced MRI. Objective response was defined as the best overall response (complete response [CR] or partial response [PR]) recorded since the first administration of treatment until disease progression, death, or treatment discontinuation.",
            "timeFrame": "During the maintenance phase at specified intervals: between days 21–28 of cycles 1, 3, 5, 8, 10, and 12 for regimen M, and of cycles 2, 4, 6, 8, 10, and 12 for regimen U; in the second year, every 3 months (cycles 15, 18, 21, and 24), and every 6 months thereafter"
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 2,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "measure": "Concentration of Afatinib in Plasma at Steady State Pre-dose on Days 8, 15 and 29",
            "description": "Concentration of afatinib in plasma at steady state pre-dose (Cpre,ss) on days 8, 15 and 29.",
            "timeFrame": "Pharmacokinetic blood sample were taken at 5 minutes before drug on days 8, 15 and 29 and 1, 3 and 6 hours after drug administration on day 15"
          },
          "pred_item": {
            "measure": "Pharmacokinetics of Afatinib",
            "description": "Afatinib concentration at steady state, measured pre-dose on specified days. Trough plasma concentrations were evaluated over time to assess consistency with previous single-agent afatinib pharmacokinetic profiles.",
            "timeFrame": "Pre-dose on Days 8, 15, and 29 of the RT phase"
          }
        }
      ]
    }
  ]
}